These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 19379636)
21. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201 [No Abstract] [Full Text] [Related]
22. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Lacouture ME; Reilly LM; Gerami P; Guitart J Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575 [TBL] [Abstract][Full Text] [Related]
23. [New drugs; sunitinib and sorafenib]. van Bronswijk H; Dubois EA; Osanto S; Cohen AF Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434 [TBL] [Abstract][Full Text] [Related]
24. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice. Kibble A; Shumoogam J IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319 [No Abstract] [Full Text] [Related]
25. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170 [TBL] [Abstract][Full Text] [Related]
26. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549 [No Abstract] [Full Text] [Related]
31. [Cutaneous side effects of sorafenib and sunitinib]. Autier J; Mateus C; Wechsler J; Spatz A; Robert C Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102 [No Abstract] [Full Text] [Related]
32. Two new drugs for renal cell carcinoma. Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624 [No Abstract] [Full Text] [Related]
33. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Girardi F; Franceschi E; Brandes AA Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589 [TBL] [Abstract][Full Text] [Related]
34. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. Sulkes A Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521 [TBL] [Abstract][Full Text] [Related]
35. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ravaud A; Sire M Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939 [No Abstract] [Full Text] [Related]
38. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? Lenihan DJ J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702 [No Abstract] [Full Text] [Related]
39. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553 [TBL] [Abstract][Full Text] [Related]
40. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]